Skip to content
Open access

Overall survival prediction and risk stratification for advanced EGFR-mutant lung adenocarcinoma patients treated with first-line tyrosine kinase inhibitors

Oct 2026 · BMC Pulmonary Medicine · 0 citations

TL;DR

Nomogram including age, EGFR genotype, serum CYFRA21-1 level, and EGFR-TKI generation can predict OS and facilitate risk stratification in patients with advanced EGFR-mutated LAD receiving first-line TKIs.

Abstract

Lung adenocarcinoma (LAD) is the most common non-small cell lung cancer subtype, with frequent epidermal growth factor receptor (EGFR) mutations in Asians. First-line tyrosine kinase inhibitors (TKIs) improves survival but resistance is inevitable, leading to disease progression and even death. We aimed to develop a predictive model for overall survival (OS) and prognostic risk stratification. In this retrospective study, patients with stage IIIB-IV EGFR-mutant LAD who received first-line TKIs and underwent pretreatment contrast-enhanced thoracic CT between January 2015 and April 2024 were enrolled. Clinicoradiological findings associated with OS were evaluated using multivariate Cox regression. The performance of the Cox regression model was assessed using the time-dependent area under the curve (AUC) and Harrell’s concordance index (C-index). Nonparametric bootstrapping with 1000 resamples was performed as internal validation to evaluate the robustness and discriminative ability of the model. A total of 250 patients (105 males and 145 females) with a mean age of 61 ± 11 years were included. The median OS was 33 (95% CI 25–37) months in patients with advanced EGFR-mutant LAD receiving TKIs. Among the EGFR subtypes, the exon 21-L858R mutation was associated with greater mortality than the exon 19- deletion mutation (HR = 1.541, P  = 0.030). Age ≥ 60 years (HR = 1.682, P  = 0.003), and CYFRA21-1 ≥ 4.5 ng/mL (HR = 1.767, P  = 0.005) were associated with relatively high mortality risk. Treatment with third-generation EGFR-TKIs (HR = 0.476, P  < 0.001) was associated with a decreased mortality risk compared with first/second-generation EGFR-TKIs. We further constructed a nomogram for predicting 12-, 24-, 36-, and 48-month OS with the AUCs of 0.745, 0.717, 0.645, and 0.673, respectively. The global C-index was 0.674. The internally validated corrected global C-index was 0.662, and the AUCs for predicting 12-, 24-, 36-, and 48-month OS were 0.766, 0.714, 0.631, and 0.672, respectively. The high-risk group had a higher risk of mortality than the low-risk group (HR = 2.558, P  < 0.001). Nomogram including age, EGFR genotype, serum CYFRA21-1 level, and EGFR-TKI generation can predict OS and facilitate risk stratification in patients with advanced EGFR-mutated LAD receiving first-line TKIs. Not applicable

Read PDF

Similar papers

Open access Oct 2026

Real-World Treatment Outcomes and Prognostic Factors in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer: A Single-Center Study from a High-Volume Tertiary Chest Hospital

The survival outcomes observed in this cohort were generally consistent with previously published real-world data in EGFR-mutant metastatic NSCLC, and ECOG performance status and bone metastasis were significantly associated with OS, while associations involving histopathological subtype and uncommon EGFR mutations sho...

A. Koçanoğlu, O. Ünsal, F. Kuş et al. · 0 citations
Open access Sep 2026

Genomic characteristics, survival, and prognostic analysis of advanced non-small cell lung cancer with KRAS mutations and brain metastases

Background The brain is a common site of metastasis in lung cancer. However, data on the incidence of brain metastases (BM) and survival outcomes among patients with non-small cell lung cancer (NSCLC) harboring KRAS mutations, particularly those receiving tyrosine kinase inhibitors (TKIs), remain limited. This single-c...

Yi Chen, Xi-He Yu, Meng-Qi Bao et al. · 0 citations
Open access Oct 2026

Prognostic Factors for Progression-Free Survival in Patients with Advanced Gastric Cancer Treated with First-Line Nivolumab Plus Oxaliplatin-Based Chemotherapy: Combined Clinical and Baseline CT Features

Background: Although nivolumab plus platinum-based chemotherapy has been approved as a first-line systemic treatment for advanced gastric cancer (AGC), the pretreatment imaging and clinical factors associated with disease progression remain incompletely understood. Methods: This retrospective study included 172 patient...

H. Rhee, Joon Seok Lim, Jin-Young Choi et al. · 0 citations
Open access Oct 2026

Development and validation of a nomogram for predicting 5-year progression-free survival probability in differentiated thyroid cancer patients with lung metastases

Background and objective Progressive disease (PD) in differentiated thyroid cancer patients with lung metastases (DTC-LM) poses a significant clinical challenge, yet reliable predictive tools remain limited. This study aimed to develop and validate a nomogram for individualized prediction of 5-year progression-free sur...

Cong-Cong Wang, Xiao-Nian Zhang, Ying-Ying Zhang et al. · 0 citations
Open access Oct 2026

Rare epidermal growth factor receptor (EGFR) mutations in completely resected stage I lung adenocarcinoma: a real-world study of mutation spectrum, clinicopathological features, and prognosis

Background Rare epidermal growth factor receptor (EGFR) mutations are heterogeneous, and their significance after complete resection of stage I lung adenocarcinoma (LUAD) remains unclear. We evaluated the mutation spectrum, clinicopathological correlates, postoperative recurrence patterns, and survival outcomes of a st...

La-Jie Man, Liang Xia, Chuan Li et al. · 0 citations
Open access Oct 2026

Predictive and Prognostic Value of Androgen Receptor Expression Across All Molecular Subtypes in Patients with Breast Cancer Who Received Neoadjuvant-Treatment: Single-Center Retrospective Analysis

Purpose Androgen receptor (AR) expression is detectable in the majority of breast cancers across all molecular subtypes; however, its predictive value for pathological complete response (pCR) and its prognostic contribution to long-term survival in an all-comer neoadjuvant chemotherapy (NACT) cohort remain incompletely...

H. Muğlu, V. B. Erol, H. Özçelik et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.